Of clinical interest, we use this dataset to assess L1 activity in tumors from individuals with Li-Fraumeni Syndrome (LFS, bearing germline TP53 pathogenic/likely pathogenic variants), and we find L1 activity in LFS cancer patients to be comparable to that in non-LFS tumors. This evidence concerns the gene TP53 and cancer.